Quality of Life Assessment Using the Leg Activity Measure in Ambulatory Individuals With Leg Spasticity: Findings From a Longitudinal, Observational Study Evaluating the Effectiveness of AbobotulinumtoxinA in Routine Practice

Objective To evaluate the effect of repeat abobotulinumtoxinA treatment on quality of life (QOL) in patients with leg spasticity. Design Secondary analysis of the prospective, longitudinal (16mo), observational AboLiSh study. Setting Specialist neurorehabilitation centers across 9 countries. Participants Ambulatory adults (66.4% men, mean age 53.9y) with unilateral lower limb spasticity able to take ≥5 steps with or without assistance. Interventions Patients were treated with abobotulinumtoxinA (up to 6 cycles) per local guidelines to achieve individualized treatment goals. Main Outcome Measures QOL was assessed at the start of each cycle using the symptom-specific Leg Activity measure (LegA; Parts A: passive function, B: active function, C: QOL impact) and the generic EQ-5D-5L scale. Results At the population level, QOL improved on both scales across the first 4 treatment cycles. LegA Part C scores decreased and EQ-5D-5L index values increased with repeat treatment. LegA Part C scores showed moderate-to-strong inverse correlations with EQ-5D-5L index values at each cycle (Pearson's R : Cycle 1: −0.66; Cycle 2: −0.57; Cycle 3: −0.60; Cycle 4: −0.59; all P